Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by FredTheVoiceon Apr 04, 2019 9:02am

146 Views

Post# 29580906

Dubuc on NASH and EGRIFTA

" gives to phisician a different perspective on the drug..."
"Change the view on the drug..."
"Will be extremely positive...."

AND LUC: "we are hiring new people to adress the question...."
"EXPANDING THE LABEL in HIV...."
"REFILING IN EUROPE.....with 10 years protection...."
AND.....third "we will look outside the HIV field..."

WOOOOOWWWW

FTV.

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario